Not provided
Not provided
Not provided
Not provided
Not provided
Per protocol, the study was terminated based on interim analysis results
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kyowa Hakko Kirin Pharma, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorectal cancer.
Phase II portion is an open-label, single arm study. Based on the results of the Phase I portion, weekly KRN330 (0.5 mg/kg) and biweekly irinotecan (180 mg/m2) will be used in the Phase II portion. To be eligible for the Phase II portion, a patient will have recurred or progressed within 6 months of the last cycle of FOLFOX/CapOx +/- bevacizumab (first-line or adjuvant regimen for metastatic colorectal cancer). Patients will continue the treatment until disease progression.
Per protocol, the decision was made to terminate the study based on interim analysis results. The Response Rate in Phase II did not meet the protocol-specified RR of 15% when 0.5 mg/kg KRN330 was administered weekly in combination with irinotecan(180 mg/m2)biweekly.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| KRN330 + Irinotecan | Experimental | open label, single arm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KRN330 | Biological | KRN330 will be dosed at 0.5 mg/kg weekly until disease progression. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0 | Until disease progression, death, or withdrawal post initial KRN330 treatment, assessed up to 100 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Kurman, MD | Kyowa Hakko Kirin Pharma, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | United States | ||
| Arizona Clinical Research Center |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | KRN330 + Irinotecan |
Phase 1 and 2Combined (N=65) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Irinotecan | Drug | Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression. |
|
| Tucson |
| Arizona |
| 85715 |
| United States |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | United States |
| Lombardi Comprehensive Cancer Center, Georgetown University Hospital | Washington D.C. | District of Columbia | 20007-2113 | United States |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | United States |
| University of Florida COllege of Medicine/Shands Cancer Center | Gainesville | Florida | 32610 | United States |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | United States |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | United States |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | United States |
| NYU Clinical Trials Office, New York University Cancer Institute | New York | New York | 10016 | United States |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | KRN330 + Irinotecan | open label, single arm |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0 | ITT population | Posted | Number | participants | Until disease progression, death, or withdrawal post initial KRN330 treatment, assessed up to 100 months |
|
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Phase 1 Regimen A: KRN330 Biweekly + IRI Biweekly | In Regimen A, patients received both KRN330 and irinotecan biweekly (Weeks 1, 3, and 5): Cohort 1: KRN330 1.0 mg/kg + irinotecan 180 mg/m2 Cohort 2: KRN330 0.5 mg/kg + irinotecan 180 mg/m2 | 6 | 12 | 12 | 12 | ||
| EG001 | Phase 1 Regimen B: KRN330 Weekly + IRI Biweekly | In Regimen B, patients received KRN330 0.5 mg/kg weekly (Weeks 1, 2, 3, 4, and 5) and irinotecan 180 mg/m2 biweekly (Weeks 1, 3, and 5) | 2 | 7 | 7 | 7 | ||
| EG002 | Phase 2: KRN330 Weekly + IRI Biweekly | The Phase 2 portion had a single arm in which patients received Regimen B as included in the Phase 1 portion | 17 | 44 | 42 | 44 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Cardiopulmonary failure | Cardiac disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Disease progression | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Streptococcal infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Clostridium difficile toxin test positive | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Metastatic pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Peripheral ischaemia | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Leukopenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Sinus tachycardia | Cardiac disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Cataract | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diplopia | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Eye pain | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lacrimation increased | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Ocular hyperaemia | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Swollen tear duct | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Vision blurred | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Visual impairment | Eye disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal distension | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abdominal wall mass | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Anorectal discomfort | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diarrhoea haemorrhagic | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Faeces discoloured | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Flatulence | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Gingival pain | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Haematochezia | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Mouth ulceration | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Oesophagitis | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Oral pain | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Proctalgia | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rectal discharge | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Application site rash | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Catheter site pain | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Chills | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Discomfort | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Gait disturbance | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypothermia | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Infusion related reaction | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Malaise | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Mucosal inflammation | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pain | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Thirst | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Portal vein thrombosis | Hepatobiliary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Fungal skin infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Furuncle | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Hordeolum | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Laryngitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Lice infestation | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Oral candidiasis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Osteomyelitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Parotitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Perirectal abscess | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Skin infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Tooth abscess | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Vulvovaginal mycotic infection | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Arthropod bite | Injury, poisoning and procedural complications | MedDRA 10.0 | Systematic Assessment |
| |
| Procedural pain | Surgical and medical procedures | MedDRA 10.0 | Systematic Assessment |
| |
| Procedural site reaction | Surgical and medical procedures | MedDRA 10.0 | Systematic Assessment |
| |
| Thermal burn | Injury, poisoning and procedural complications | MedDRA 10.0 | Systematic Assessment |
| |
| Wound | Injury, poisoning and procedural complications | MedDRA 10.0 | Systematic Assessment |
| |
| Wound secretion | Injury, poisoning and procedural complications | MedDRA 10.0 | Systematic Assessment |
| |
| Activated partial thromboplastin time prolonged | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood alkaline phosphatase increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood bicarbonate decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood magnesium decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood potassium decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood pressure decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood pressure increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood sodium decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Blood uric acid increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Body temperature increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Breath sounds abnormal | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Clostridium difficile toxin test positive | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Haemoglobin decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Neutrophil count decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Platelet count decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Skin turgor decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Weight increased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| White blood cell count decreased | Investigations | MedDRA 10.0 | Systematic Assessment |
| |
| Anorexia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperamylasaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypercalcaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypophosphataemia | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lactic acidosis | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Malnutrition | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Vitamin B12 deficiency | Metabolism and nutrition disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Bone pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Jaw disorder | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Joint swelling | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Musculoskeletal discomfort | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Ageusia | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Altered state of consciousness | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Cholinergic syndrome | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dysarthria | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperaesthesia | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lethargy | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Memory impairment | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Neuropathy peripheral | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Poor quality sleep | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Presyncope | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Confusional state | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Restlessness | Psychiatric disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dysuria | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Incontinence | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pollakiuria | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Proteinuria | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Urinary incontinence | Renal and urinary disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Erectile dysfunction | Reproductive system and breast disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Haematospermia | Reproductive system and breast disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pruritus genital | Reproductive system and breast disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Scrotal erythema | Reproductive system and breast disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Vulvovaginal burning sensation | Reproductive system and breast disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Asthma | Immune system disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dysphonia | Ear and labyrinth disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Epistaxis | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hiccups | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Increased upper airway secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lung disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Lung infiltration | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Paranasal sinus hypersecretion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rales | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rhinorrhoea | Infections and infestations | MedDRA 10.0 | Systematic Assessment |
| |
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Acne | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dandruff | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dermatitis exfoliative | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Eczema | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Exfoliative rash | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Night sweats | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pruritus generalised | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rash erythematous | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rash generalised | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rash papular | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Rash pruritic | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Skin lesion | Skin and subcutaneous tissue disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Flushing | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Pallor | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Peripheral arterial occlusive disease | Vascular disorders | MedDRA 10.0 | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Project Leader | KYOWA KIRIN PHARMA | 6099191100 | clinical.info@kyowa-kirin-pharma.com |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D007414 | Intestinal Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D009369 | Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C581257 | KRN-330 |
| D000077146 | Irinotecan |
| ID | Term |
|---|---|
| D002166 | Camptothecin |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided